Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohammad Ali Omrani

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
British Journal of Clinical Pharmacology|January 20, 2026
Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic reviewBala Swetha Baskaran, Mohammad Ali Omrani, Flory T Muanda
Journal of Psychopharmacology (Oxford, England)|July 24, 2025
β-blockers and risk of neuropsychiatric adverse events: An active-comparator restricted disproportionality on the FAERSLujain Ez Eddin, Mohammad Ali Omrani, Niaz Chalabianloo, et al.
Journal of Food Protection|March 14, 2023
Human Health Risk Assessment and Exposure Evaluation by Monte-Carlo Simulation Method for Aflatoxin M1 in Widely Consumed Infant Dried Powder Milk in IranBehnaz Naghshbandi, Mohammad Ali Omrani, Abolfazl Jafari-Sales, et al.
Plos One|September 25, 2025
Enhancing adverse drug reaction data quality in Canada: A high-precision pipeline for medication name standardization and enrichmentNiaz Chalabianloo, Sheikh S Abdullah, Mohammad Ali Omrani, et al.
British Journal of Clinical Pharmacology|December 10, 2024
β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysisLujain Ez Eddin, Rebecca Preyra, Fatemeh Ahmadi, et al.
Journal of Psychopharmacology (Oxford, England)|June 27, 2025
Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System databaseMohammad Ali Omrani, Christian T Tsobo, Niaz Chalabianloo, et al.
The Journal of Antimicrobial Chemotherapy|July 15, 2025
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERSRinko Lau, Hasti Sadeghi, Fatemeh Ahmadi, et al.
Expert Opinion on Drug Safety|March 5, 2026
Who is missing from SGLT-2 inhibitor trials? implications for drug safety and seneralizability: a systematic review and meta-analysisMohammad Ali Omrani, Bala Swetha Baskaran, Hasti Sadeghi, et al.
The Annals of Pharmacotherapy|February 27, 2025
Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) DatabaseFatemeh Ahmadi, Niaz Chalabianloo, Eric McArthur, et al.
The American Journal of Emergency Medicine|October 1, 2025
Comparative effectiveness of vasopressin, steroids, and epinephrine-based regimens in cardiac arrest: A network Meta-analysis of clinical trialsFatemeh Saghafi, Mohammad Hossein Dehghani, Sajjad Erami, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|January 20, 2026
Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic reviewBala Swetha Baskaran, Mohammad Ali Omrani, Flory T Muanda
Journal of Psychopharmacology (Oxford, England)|July 24, 2025
β-blockers and risk of neuropsychiatric adverse events: An active-comparator restricted disproportionality on the FAERSLujain Ez Eddin, Mohammad Ali Omrani, Niaz Chalabianloo, et al.
Journal of Food Protection|March 14, 2023
Human Health Risk Assessment and Exposure Evaluation by Monte-Carlo Simulation Method for Aflatoxin M1 in Widely Consumed Infant Dried Powder Milk in IranBehnaz Naghshbandi, Mohammad Ali Omrani, Abolfazl Jafari-Sales, et al.
Plos One|September 25, 2025
Enhancing adverse drug reaction data quality in Canada: A high-precision pipeline for medication name standardization and enrichmentNiaz Chalabianloo, Sheikh S Abdullah, Mohammad Ali Omrani, et al.
British Journal of Clinical Pharmacology|December 10, 2024
β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysisLujain Ez Eddin, Rebecca Preyra, Fatemeh Ahmadi, et al.
Journal of Psychopharmacology (Oxford, England)|June 27, 2025
Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System databaseMohammad Ali Omrani, Christian T Tsobo, Niaz Chalabianloo, et al.
The Journal of Antimicrobial Chemotherapy|July 15, 2025
Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERSRinko Lau, Hasti Sadeghi, Fatemeh Ahmadi, et al.
Expert Opinion on Drug Safety|March 5, 2026
Who is missing from SGLT-2 inhibitor trials? implications for drug safety and seneralizability: a systematic review and meta-analysisMohammad Ali Omrani, Bala Swetha Baskaran, Hasti Sadeghi, et al.
The Annals of Pharmacotherapy|February 27, 2025
Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) DatabaseFatemeh Ahmadi, Niaz Chalabianloo, Eric McArthur, et al.
The American Journal of Emergency Medicine|October 1, 2025
Comparative effectiveness of vasopressin, steroids, and epinephrine-based regimens in cardiac arrest: A network Meta-analysis of clinical trialsFatemeh Saghafi, Mohammad Hossein Dehghani, Sajjad Erami, et al.
Pageof 2